Compounds > clarithromycin
Page last updated: 2024-08-25

clarithromycin and Pseudomonas Infections

clarithromycin has been researched along with Pseudomonas Infections in 30 studies

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (16.67)18.2507
2000's12 (40.00)29.6817
2010's13 (43.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aguilera-Correa, JJ; Esteban, J; García-Coca, M; Mahíllo-Fernández, I; Pérez-Jorge, C; Rodríguez-Sevilla, G; Romera-García, D1
Adamopoulou, M; Giamarellos-Bourboulis, EJ; Kotanidou, A; Orfanos, SE; Raftogiannis, M; Renieris, G; Routsi, C; Sabracos, L; Strouvalis, I1
Bergamini, G; Boaretti, M; Boschi, F; Cremonini, E; Lleo, M; Melotti, P; Ortombina, A; Sandri, A; Sorio, C1
Giamarellos-Bourboulis, EJ; Karagianni, V; Liakou, P; Menenakos, E; Sabracos, L; Spyridaki, A; Tsaganos, T; Tsovolou, EC; Tzepi, IM; Zografos, G1
Elkhatib, W; Noreddin, A1
Cucurachi, M; Faneschi, ML; Lobreglio, G; Miglietta, F; Palumbo, C; Pizzolante, M; Velardi, L1
Ali-Dinar, T; Colin, AA1
Kádár, B; Kristóf, K; Krizsán, G; Nagy, K; Pesti, N; Rókusz, L; Szabó, D; Szász, M; Szentandrássy, J1
Brescini, L; Cirioni, O; Gabrielli, E; Ghiselli, R; Giacometti, A; Guerrieri, M; Minardi, D; Muzzonigro, G; Orlando, F; Rimini, M; Silvestri, C1
Ding, FM; Jiang, YQ; Shen, C; Zhu, SL1
Choujin, Y; Hara, K; Hisaoka, M; Ishimoto, H; Kido, T; Mukae, H; Nagata, S; Yamaga, C; Yamasaki, K; Yatera, K1
Cash, HL; Fujita, J1
Hosogaya, N; Imamura, Y; Ishimatu, Y; Izumikawa, K; Kakeya, H; Kohno, S; Miyazaki, T; Morinaga, Y; Nakamura, S; Sakamoto, N; Yamamoto, Y; Yanagihara, K; Yasuoka, A1
Baba, S; Furuhata, M; Inoue, M; Iwamura, M1
Hirakata, Y; Kadota, J; Kaneko, Y; Kohno, S; Kuroki, M; Miyazaki, Y; Mukae, H; Seki, M; Tomono, K; Yanagihara, K1
Adamis, T; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Laoutaris, G; Mouktaroudi, M; Perrea, D; Sabracos, L1
Bayarslan, C; Bayramoğlu, A; Celik, HH; Kandemir, O; Kaya, A; Milcan, A; Oztuna, V1
Adamis, T; Antonopoulou, A; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Panagou, C; Raftogiannis, M; Tsaganos, T; Tziortzioti, V1
Higashiyama, Y; Higuchi, N; Hirakata, Y; Kadota, J; Kohno, S; Kuroki, M; Miyazaki, Y; Mizuta, Y; Mukae, H; Ohno, H; Tomono, K; Tsukamoto, K; Yanagihara, K1
Adamis, T; Baziaka, F; Chrisofos, M; Douzinas, EE; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Raftogiannis, M; Sabracos, L; Tziortzioti, V1
Hirose, T; Kumamoto, Y; Nishimura, M; Ohya, S; Sano, M; Tsukamoto, T1
Ohgaki, N1
Ajiki, Y; Kawada, H; Koga, T; Yasuda, H; Yokota, T1
Guzmán, CA; Molinari, G; Pesce, A; Schito, GC1
Hirakata, Y; Kadota, J; Koga, H; Kohno, S; Sawai, T; Tashiro, T; Tomono, K; Yanagihara, K1
Banevicius, MA; Bui, KQ; Nicolau, DP; Nightingale, CH; Quintiliani, R1
Higashiyama, Y; Hirakata, Y; Kadota, J; Kaneko, Y; Kohno, S; Kuroki, M; Maesaki, S; Miyazaki, Y; Ohno, H; Sawai, T; Tashiro, T; Tomono, K; Yanagihara, K1
Higashiyama, Y; Kadota, J; Kaneko, Y; Kohno, S; Kuroki, M; Maesaki, S; Miyazaki, Y; Ohno, H; Sawai, T; Tomono, K; Yanagihara, K1
Kantrow, SP; Knower, MT; Labella-Walker, K; McFadden, PM; Valentine, VG1
Hirakata, Y; Imamura, Y; Kadota, J; Kaneko, Y; Kohno, S; Kuroki, M; Miyazaki, Y; Mukae, H; Sawai, T; Tomono, K; Yanagihara, K1

Reviews

1 review(s) available for clarithromycin and Pseudomonas Infections

ArticleYear
Two cases of primary ciliary dyskinesia with different responses to macrolide treatment.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:9

    Topics: Adolescent; Aged; Anti-Bacterial Agents; Clarithromycin; Humans; Kartagener Syndrome; Macrolides; Male; Pseudomonas Infections; Treatment Outcome

2012

Trials

1 trial(s) available for clarithromycin and Pseudomonas Infections

ArticleYear
Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence.
    Respirology (Carlton, Vic.), 2018, Volume: 23, Issue:10

    Topics: Animals; Anti-Bacterial Agents; APACHE; Biomarkers; Bronchoalveolar Lavage Fluid; Clarithromycin; Double-Blind Method; Humans; Interferon-gamma; Interleukin-1beta; Mice; Peroxidase; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2018

Other Studies

28 other study(ies) available for clarithromycin and Pseudomonas Infections

ArticleYear
Non-Tuberculous Mycobacteria multispecies biofilms in cystic fibrosis: development of an in vitro Mycobacterium abscessus and Pseudomonas aeruginosa dual species biofilm model.
    International journal of medical microbiology : IJMM, 2018, Volume: 308, Issue:3

    Topics: Anti-Bacterial Agents; Biofilms; Clarithromycin; Cystic Fibrosis; Humans; In Vitro Techniques; Models, Biological; Mycobacterium abscessus; Nontuberculous Mycobacteria; Pseudomonas aeruginosa; Pseudomonas Infections

2018
Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice.
    Virulence, 2018, Volume: 9, Issue:1

    Topics: Animals; Bacterial Proteins; Clarithromycin; Cystic Fibrosis; Disease Models, Animal; Female; Humans; Interleukin-8; Lung; Mice; Mice, Inbred C57BL; Mice, Knockout; Pseudomonas aeruginosa; Pseudomonas Infections; Virulence Factors

2018
Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2014, Volume: 122, Issue:1

    Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Apoptosis; Clarithromycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Empyema, Pleural; Humans; Interleukin-6; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pleural Effusion; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tumor Necrosis Factor-alpha; U937 Cells

2014
Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model.
    Microbial drug resistance (Larchmont, N.Y.), 2014, Volume: 20, Issue:6

    Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; In Vitro Techniques; Microbial Sensitivity Tests; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections

2014
A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2016, Volume: 29, Issue:1

    Topics: Anti-Bacterial Agents; Antifungal Agents; Clarithromycin; Fungemia; Geotrichosis; Geotrichum; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas Infections; Superinfection

2016
Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up.
    Pediatric pulmonology, 2010, Volume: 45, Issue:6

    Topics: Administration, Oral; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Cystic Fibrosis; Drug Therapy, Combination; Female; Forced Expiratory Volume; Gram-Negative Bacterial Infections; Humans; Mycobacterium; Mycobacterium Infections; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia

2010
In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
    Acta microbiologica et immunologica Hungarica, 2010, Volume: 57, Issue:3

    Topics: Anti-Bacterial Agents; Biofilms; Clarithromycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections

2010
Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:6

    Topics: Amikacin; Animals; Anti-Bacterial Agents; Biofilms; Clarithromycin; Coated Materials, Biocompatible; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Stents; Ureteral Diseases

2011
Low-dose clarithromycin therapy modulates CD4(+) T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection.
    Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage; Clarithromycin; Disease Models, Animal; Female; Immunohistochemistry; Interleukin-17; Interleukin-4; Lung Diseases; Mice; Mice, Inbred BALB C; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; Respiratory Tract Infections; Stem Cells; T-Lymphocytes, Regulatory

2012
Long-term combination treatment of azithromycin with other macrolides: a new era.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:11

    Topics: Azithromycin; Clarithromycin; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections

2012
A case of refractory chronic respiratory tract infection due to Pseudomonas aeruginosa successfully controlled by combination of clarithromycin and azithromycin.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:11

    Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Treatment Outcome

2012
Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty.
    International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:4

    Topics: Adult; Biofilms; Cilastatin; Clarithromycin; Drug Therapy, Combination; Humans; Imipenem; Kidney Calculi; Kidney Pelvis; Male; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Staphylococcal Infections; Staphylococcus epidermidis; Treatment Outcome; Ureteral Obstruction

2003
Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis.
    American journal of physiology. Lung cellular and molecular physiology, 2003, Volume: 285, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Bronchiolitis; Bronchoalveolar Lavage Fluid; Cell Count; Clarithromycin; Colony Count, Microbial; Lung; Mice; Mitogen-Activated Protein Kinases; Mucin 5AC; Mucins; Pseudomonas Infections

2003
Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1

    Topics: Acute Disease; Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Immunity; Lipopolysaccharides; Male; Malondialdehyde; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Sepsis; Survival Analysis; Tumor Necrosis Factor-alpha

2004
Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis.
    Clinical orthopaedics and related research, 2005, Issue:430

    Topics: Animals; Anti-Bacterial Agents; Biofilms; Clarithromycin; Colony Count, Microbial; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Microbial Sensitivity Tests; Osteomyelitis; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Rats; Rats, Wistar; Reference Values

2005
Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
    BMC infectious diseases, 2006, Feb-21, Volume: 6

    Topics: Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Immunologic Factors; Kidney; Lipopolysaccharides; Liver; Lung; Male; Malondialdehyde; Monocytes; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Spleen; Tumor Necrosis Factor-alpha

2006
Telithromycin inhibits the number of viable bacteria but not lymphocyte accumulation in a murine model of chronic respiratory infection.
    Chemotherapy, 2007, Volume: 53, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Ketolides; Lung; Lymphocytes; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections

2007
Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Humans; Immunologic Factors; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Sepsis

2008
[Inhibition of biofilm formation by clarithromycin (CAM) in an experimental model of complicated bladder infection--in vitro study using automated simulation of urinary antimicrobial concentration].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1994, Volume: 68, Issue:11

    Topics: Biofilms; Cells, Cultured; Clarithromycin; Glycoproteins; Humans; Microbial Sensitivity Tests; Polysaccharides; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Bladder Diseases; Urine

1994
Bacterial biofilm in chronic airway infection.
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1994, Volume: 68, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Bacterial Adhesion; Bronchiectasis; Bronchoalveolar Lavage Fluid; Chemotaxis; Chronic Disease; Clarithromycin; Humans; In Vitro Techniques; Lung; Male; Mice; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections

1994
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
    Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:9

    Topics: Alginates; Animals; Bacterial Proteins; Clarithromycin; Filtration; Hexoses; Male; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Skin

1993
Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.
    The Journal of antimicrobial chemotherapy, 1993, Volume: 31, Issue:5

    Topics: Anti-Bacterial Agents; Azithromycin; Cell Movement; Clarithromycin; Erythromycin; Hemolysin Proteins; Humans; Lipase; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Virulence

1993
Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection.
    American journal of respiratory and critical care medicine, 1997, Volume: 155, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Bronchiolitis; CD4-CD8 Ratio; Chronic Disease; Clarithromycin; Lung; Lymphocytes; Mice; Pseudomonas aeruginosa; Pseudomonas Infections

1997
In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 45, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors

2000
Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:1

    Topics: Animals; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Intubation; Levofloxacin; Male; Mice; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections

2000
Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa.
    Clinical and experimental immunology, 2000, Volume: 122, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Bronchiolitis; Clarithromycin; Cytokines; Disease Models, Animal; Interferon-gamma; Interleukin-1; Interleukin-2; Interleukin-4; Interleukin-5; Lung; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tissue Extracts; Tumor Necrosis Factor-alpha

2000
Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients.
    Southern medical journal, 2000, Volume: 93, Issue:11

    Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Cyclosporine; Female; Follow-Up Studies; Graft Rejection; Humans; Hypertension; Immunosuppressive Agents; Kidney; Lung Transplantation; Male; Matched-Pair Analysis; Postoperative Complications; Pseudomonas Infections; Transplantation, Homologous

2000
Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.
    The Journal of antimicrobial chemotherapy, 2002, Volume: 49, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Biofilms; Chronic Disease; Clarithromycin; Josamycin; Male; Mice; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Pseudomonas Infections; Respiratory Tract Infections

2002